Fujian Wanchen Biotechnology Co. Ltd (300972) - Total Liabilities
Based on the latest financial reports, Fujian Wanchen Biotechnology Co. Ltd (300972) has total liabilities worth CN¥7.34 Billion CNY (≈ $1.07 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fujian Wanchen Biotechnology Co. Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how Fujian Wanchen Biotechnology Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See 300972 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Fujian Wanchen Biotechnology Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Fujian Wanchen Biotechnology Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Greek Organization of Football Prognostics S.A.
AT:OPAP
|
Greece | €1.75 Billion |
|
China Nonferrous Mining Corporation Limited
STU:3N4
|
Germany | €1.39 Billion |
|
EFG International AG
SW:EFGN
|
Switzerland | CHF37.01 Billion |
|
TPG Telecom Ltd
AU:TPG
|
Australia | AU$7.93 Billion |
|
Mercury Systems Inc
NASDAQ:MRCY
|
USA | $1.04 Billion |
|
SFS Group AG
SW:SFSN
|
Switzerland | CHF893.90 Million |
|
RTL Group SA
F:RRTL
|
Germany | €4.97 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Fujian Wanchen Biotechnology Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 300972 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fujian Wanchen Biotechnology Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fujian Wanchen Biotechnology Co. Ltd (2019–2025)
The table below shows the annual total liabilities of Fujian Wanchen Biotechnology Co. Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥7.50 Billion ≈ $1.10 Billion |
+29.43% |
| 2024-12-31 | CN¥5.79 Billion ≈ $847.56 Million |
+79.35% |
| 2023-12-31 | CN¥3.23 Billion ≈ $472.58 Million |
+510.75% |
| 2022-12-31 | CN¥528.79 Million ≈ $77.38 Million |
+151.24% |
| 2021-12-31 | CN¥210.47 Million ≈ $30.80 Million |
-18.40% |
| 2020-12-31 | CN¥257.94 Million ≈ $37.74 Million |
-17.01% |
| 2019-12-31 | CN¥310.81 Million ≈ $45.48 Million |
-- |
About Fujian Wanchen Biotechnology Co. Ltd
Fujian Wanchen Biotechnology Co., Ltd., together with its subsidiaries, engages in the research, development, cultivation, production, and sale of edible fungi in China and internationally. The company offers enoki and golden enoki, white jade, crab, seafood, deer antler, oyster, and other mushrooms products, as well as flammulina velutipes, hydrangea edulis, and pleurotus eryngii. It is also inv… Read more